Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

Patients who received glucagon-like peptide-1 receptor agonists had fewer 90-day complications vs. patients who did not receive the medication. There was no difference in 2-year revision rates ...

Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients with type 2 ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a ...

About The Study: In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated with increased risk of psychiatric adverse ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

GLP-1 agonists, medications commonly used for weight loss and type 2 diabetes, may also help reduce alcohol intake — an ...